

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known			
		Application Number	09/445,328 (Conf. No. 9813)		
		Filing Date	December 7, 1999		
		First Named Inventor	Kuber Sampath		
		Art Unit	1647		
		Examiner Name	David S. Romeo		
Sheet	1	of	4	Attorney Docket	STK-P01-514

U. S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² *****			
		us-5,723,441	03/03/1998	Higley et al.	
		us-5,849,686	12/15/1998	Kuberasampath et al.	
		us-5,879,908	03/09/1999	Laping et al.	
		us-6,120,760	09/19/2000	Hotten et al.	
		us-6,498,142	12/24/2002	Sampath et al.	
		us-6,861,404	03/01/2005	Cohen et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ *Number ⁴ *Kind Code ⁵ (if known)				
		CA 1128881	08/03/1982	Morinaga Milk Industry Co., Ltd. And Green Cross Corporation		
		WO 92/15323	09/17/1992	Creative Biomolecules, Inc.		
		WO 93/05172	03/18/1993	Creative Biomolecules, Inc.		
		WO 94/03075	02/17/1994	Creative Biomolecules, Inc.		
		WO 94/03600	02/17/1994	Creative Biomolecules, Inc.		
		WO 94/06449	03/31/1994	Creative Biomolecules, Inc.		
		WO 94/20539	09/15/1994	Creative Biomolecules, Inc.		
		WO 95/08621	03/30/1995	Creative Biomolecules, Inc.		
		WO 95/11983	05/04/1995	Creative Biomolecules, Inc.		

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T ⁶
		AVNER, "Polypeptide growth factors in metanephric growth and segmental nephron differentiation," <i>Pediatr. Nephrol.</i> , 4:372-377 (1990).			
		BARD et al., "Towards a genetic basis for kidney development," <i>Mech. Develop.</i> , 48:3-11 (1994).			

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). * For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DR/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	09/445,328 (Conf. No. 9813)		
		Filing Date	December 7, 1999		
		First Named Inventor	Kuber Sampath		
		Art Unit	1647		
		Examiner Name	David S. Romeo		
Sheet	2	of	4	Attorney Docket	STK-P01-514

NON PATENT LITERATURE DOCUMENTS		
	BASIC, "The role of bone morphogenetic proteins in renal compensatory growth," <i>Lijecnicki Vjesnik</i> , HR, Uredništvo Lijecnickog Vjesnika; Zagreb, 119(2):53-55 (1997) ISSN: 0024-3477, CODEN: LIVJA5.	T
	BORDER et al., "Suppression of experimental glomerulonephritis by antiserum against transforming growth factor β 1," <i>Nature</i> , 346:371-374 (1990).	
	BRENNER et al., "Chronic renal failure," <i>Harrison's principles of internal medicine</i> , 13th ed., Isselbacher et al. (Eds.), Chpt. 238, pp. 1274-1281 (New York: McGraw-Hill, 1994).	
	CARPENTER et al., "Dialysis and transplantation in the treatment of renal failure," <i>Harrison's principles of internal medicine</i> , 13th ed., Isselbacher et al. (Eds.), Chpt. 238, pp. 1281-1282 (New York: McGraw-Hill, 1994).	
	COE et al., "Approach to the patient with diseases of the kidneys and urinary tract," <i>Harrison's principles of internal medicine</i> , 13th ed., Isselbacher et al. (Eds.), Chpt. 237, pp. 1252 (New York: McGraw-Hill, 1994).	
	DUDLEY et al., "A requirement for bone morphogenetic protein-7 during development of the mammalian kidney and eye," <i>Genes & Devel.</i> , 9:2795-2807 (1995).	
	FLOEGE et al., "Glomerular cells, extracellular matrix accumulation, and the development of glomerulosclerosis in the remnant kidney model," <i>Laboratory Investigation</i> , 66(4):485-497 (1992).	
	GLASSOCK, "Immunosuppressive treatment in the prevention of renal failure in primary glomerular diseases," <i>Clin. Exp. Dial. Apheresis</i> , 5(1-2):21-46 (1981).	
	GLASSOCK et al., "Immunopathogenic mechanisms of renal injury," <i>Harrison's principles of internal medicine</i> , 13th ed., Isselbacher et al. (Eds.), Chpt. 239, pp. 1292-1295 (New York: McGraw-Hill, 1994).	
	GULER et al., "Effects of recombinant insulin-like growth factor I on insulin secretion and renal function in normal human subjects," <i>Proc. Natl. Acad. Sci. (USA)</i> , 86:2868-2872 (1989).	
	HAMAGUCHI et al., "Transforming growth factor- β 1 expression and phenotypic modulation in the kidney of hypertensive rats," <i>Hypertension</i> , 26(1):199-207 (1995).	
	HIRSCHBERG et al., "Effects of insulin-like growth factor I on renal function in normal men," <i>Kidney Intl.</i> 43:387-397 (1993).	
	JENNERHOLM et al., "Magnetic resonance imaging of the transplanted kidney. Correlation to function and histopathology," <i>Acta Radiologica</i> , 31(5):499-503 (1990).	
Examiner Signature		Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). * For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DR/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	09/445,328 (Conf. No. 9813)		
		Filing Date	December 7, 1999		
		First Named Inventor	Kuber Sampath		
		Art Unit	1647		
		Examiner Name	David S. Romeo		
Sheet	3	of	4	Attorney Docket	STK-P01-514

NON PATENT LITERATURE DOCUMENTS		
	JONES et al., "Involvement of bone morphogenetic protein-4 (BMP-4) and Vgr-1 in morphogenesis and neurogenesis in the mouse," <i>Development</i> , 111:531-542 (1991).	
	KEES-FOLTS et al., "Relationship between hyperlipidemia, lipid mediators, and progressive glomerulosclerosis in the nephrotic syndrome," <i>Am. J. Nephrol.</i> , 13(5):365-375 (1993).	
	KLAHR et al., "The progression of renal disease," <i>N. Eng. J. Med.</i> , 318(25):1657-1666 (1988).	
	KOPPLE, "The rationale for the use of growth hormone or insulin-like growth factor I in adult patients with renal failure," <i>Miner. Electrolyte Metab.</i> , 18:269-275 (1992).	
	LEMANN et al., "Use of the serum creatinine to estimate glomerular filtration rate in health and early diabetic nephropathy. Collaborative Study Group of Angiotensin Converting Enzyme Inhibition in Diabetic Nephropathy," <i>Am. J. Kidney Dis.</i> , 3:236-243 (1990).	
	LUO et al., "BMP-7 is an inducer of nephrogenesis, and is also required for eye development and skeletal patterning," <i>Genes & Devel.</i> , 9:2808-2820 (1995).	
	MILLER et al., "Effects of IGF-I on renal function in end-stage chronic renal failure," <i>Kidney Intl.</i> , 46:201-207 (1994).	
	Notice of Allowance mailed December 15, 2008 for Serial No. 11/016,499	
	OZKAYNAK et al., "Murine osteogenic protein (OP-1): High levels of mRNA in kidney," <i>Biochem. Biophys. Res. Comm.</i> , 179(1):116-123 (1991).	
	OZKAYNAK et al., "Osteogenic protein-2: A new member of the transforming growth factor- β superfamily expressed early in embryogenesis," <i>J. Biol. Chem.</i> , 267(35):25220-25227 (1992).	
	PONTICELLI et al., "Conventional treatment of idiopathic nephrotic syndrome and membranous nephropathy in adults," <i>Clin. Nephrol.</i> , 35(S1):S16-S21 (1991).	
	SAMAAN et al., "Growth hormone levels in severe renal failure," <i>Metabolism</i> , 19(2):102-113 (1970).	
	SCHILLER et al., "Focal glomerulosclerosis in the remnant kidney model--an inflammatory disease mediated by cytokines," <i>Nephrology, Dialysis, Transplantation</i> , 12(3):430-437 (1997).	
	SHANKLAND et al., "Expression of transforming growth factor- β 1 during diabetic renal hypertrophy," <i>Kidney Intl.</i> , 46:430-442 (1994).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ² Applicant's unique citation designation number (optional). ³ See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ⁴ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁷ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DR/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	09/445,328 (Conf. No. 9813)
				Filing Date	December 7, 1999
				First Named Inventor	Kuber Sampath
				Art Unit	1647
				Examiner Name	David S. Romeo
Sheet	4	of	4	Attorney Docket	STK-P01-514

NON PATENT LITERATURE DOCUMENTS		
	TAMAKI et al., "TGF- β 1 in glomerulosclerosis and interstitial fibrosis of adriamycin nephropathy," <i>Kidney Intl.</i> , 45:525-536 (1994).	
	TOBACK, "Regeneration after acute tubular necrosis," <i>Kidney Intl.</i> , 41:226-246 (1992).	
	TOLINS et al., "Mechanisms of hypertensive glomerular injury," <i>Am. J. Cardiol.</i> , 62(11):54G-58G (1988).	
	VUKICEVIC et al., "Localization of osteogenic protein-1 (Bone Morphogenetic Protein-7) during human embryonic development: High affinity binding to basement membranes," <i>Biochem. Biophys. Res. Comm.</i> , 198(2):693-700 (1994).	
	VUKICEVIC et al., "Developing human lung and kidney are major sites for synthesis of bone morphogenetic protein-3 (Osteogenin)," <i>J. Histochem. Cytochem.</i> , 42(7):869-875 (1994).	
	VUKICEVIC et al., "Recombinant human OP-1 (BMP-7) prevents rapid loss of glomerular function and improves mortality associated with chronic renal failure," <i>J. Am. Soc. Nephrol.</i> , 7(9):1867 (1996).	
	WATANABE et al., "Production of hydrogen peroxide by neutrophilic polymorphonuclear leukocytes in patients with diabetic nephropathy," <i>J. Clin. Lab. Anal.</i> , 7(4):209-213 (1993).	
	WRIGHT et al., "Serum-growth hormone and glucose intolerance in renal failure," <i>The Lancet</i> , 2:798-800 (1968).	
	YAMAMOTO et al., "Expression of transforming growth factor β is elevated in human and experimental diabetic nephropathy," <i>Proc. Natl. Acad. Sci. (USA)</i> , 90:1814-1818 (1993).	
	YAMAMOTO et al., "Sustained expression of TGF- β 1 underlies development of progressive kidney fibrosis," <i>Kidney Intl.</i> , 45:916-927 (1994).	
	YANG et al., "Local macrophage and myofibroblast proliferation in progressive renal injury in the rat remnant kidney," <i>Nephrology, Dialysis, Transplantation</i> , 13(8):1967-1974 (1998).	

Examiner Signature	/David Romeo/ (05/07/2009)	Date Considered	
--------------------	----------------------------	-----------------	--

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ² Applicant's unique citation designation number (optional). ³ See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ⁴ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁷ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DR/